Type 2 diabetes and hypercholesterolemia both arise from a combination of genetic predisposition and environmental/lifestyle factors, but treatment practices for these conditions have taken a purely phenotypic approach. Learn how personalised medicine is being applied to treatment decisions in these two conditions, in order to individualise therapy and reduce the risk of cardiovascular morbidity and mortality.
Summary
Introduction : Definitions & Objectives of the colloquium: Selective choices among relevant areas with established therapeutic progress. Dominique BELLET et Jean-Paul TILLEMENT
New diagnostic and Therapeutic Technologies
Integration of individual genetic and kinetic characteristics for the pharmacological optimization of drug use. Pierre MARQUET
Toward precision medicine for age-related diseases: standardized geriatric assessment. Fati NOURHASHEMI
Genomic and precision medicine: setting problems and perspectives. Francis GALIBERT
Managing drug interactions: a clinical decision support system. Jacques TURGEON
Therapeutic targeting of Interleukin 17: An example of translational medicine. Pierre MIOSSEC
Realities and perspetives of precision medicine
Type 2 diabetes and hypercholesterolemia. André SCHEEN
Should we sequence each patient's tumour? Christophe LE TOURNEAU
Kidney transplantation: an emblematic example of precision medicine to solve an increasingly complex situation. Thierry HAUET
Gene, cellular and stem-cell therapies: perspectives and limits. Salima HACEIN-BEY
Precision Medicine: which applications, cost and targeted populations? Jean-Pierre MICHEL
Organizers
Authors
Organizers
Authors
Category
The patient
Publication type
Proceedings
Year
2017
Download the publication